Emcutix Biopharmaceuticals in collaboration with its Canada-based subsidiary Mantra Pharma has announced the pan-India launch of Ureaderm 10% & 20%, a urea-based moisturizer in cream formulation, for the prevention and management of extremely dry skin conditions and hyperkeratotic conditions such as psoriasis and ichthyosis, respectively. The moisturizer is designed to restore skin’s natural moisturizing factor and boost hydration levels.

Global studies have shown urea concentrations between 5% and 40% to be effective against dry skin conditions. Building on this scientific foundation, Ureaderm has been uniquely formulated to deliver enhanced and long-lasting hydration through the integration of advanced Multilayer Fatty Acid Emulsion (MLFAE) technology. This technology enables a sustained release of urea, ensuring deep hydration and continuous moisturization for up to 72 hours. In addition to urea, the formulation includes eicosapentaenoic acid (EPA), Gamma-linolenic acid (GLA) and allantoin, which work together to strengthen the skin’s lipid barrier, reduce water loss and keep skin soft, supple and healthy.

“We understand that modern skincare demands more than regular moisturising—they require formulations grounded in rigorous science with real-world efficacy. By integrating controlled-release encapsulation with optimized urea levels, the product ensures continuous skin barrier support that provides therapeutic benefits for conditions like ichthyosis and psoriasis,” shares Sathya Narayanan, CEO, Emcutix Biopharmaceuticals Ltd. “Above all, we remain committed to making performance-driven, evidence-based skincare solutions both accessible and affordable for consumers.”